【Product Category】The fourth-generation cephalosporin

【Indications】

This product is indicated for the treatment of moderate to severe infections caused by susceptible organisms for adults and children (2 months to 16 years old), including LRTI-lower respiratory tract infection (pneumonia and bronchitis), uncomplicated LUTI-lower urinary tract infection/CUTI-complicated urinary tract infection (pyelonephritis included), uncomplicated skin and skin soft tissue infection, complicated intra-abdominal infection (peritonitis and biliary tract infection included), gynaecology and obstetrics infection, sepsis, and empiric therapy of neutropenic patients with fever, and also for the treatment of bacterial cerebrospinal meningitis in children.

Germiculture and drug susceptibility test should be performed when with suspected bacterial infection; however, Cefepime is a broad-spectrum microbicide inhibiting both gram-positive and gram-negative organisms, then monotherapy using Cefepime can be initiated before obtaining results of susceptibility test. Combination with other anti-anaerobic medicine (e.g.: metronidazole) is suggested for initial treatment of suspected mixed infection of anaerobe, which shall be timely adjusted once the results of germiculture and drug susceptibility test are available.

【Dosage and Administration】

This product can be administrated through intravenous drip or deep intramuscular injection. For adults and children above 16 years old or whose weights are 40 kg or above, depending on their condition, 1-2 g per dose every 12 hours through intravenous drip, 7-10 days as a course. More details on the specification in the package insert.

【Strength】1.0 g (calculated on the basis of C₁₉H₂₄N₆O₅S₂)